Nephropathic cystinosis: effect of long-term cysteamine therapy. 1987

W Proesmans, and E Baten, and J Hoogmartens, and P Bruyneel

Three children with nephropathic cystinosis received cysteamine therapy, mostly in the form of phosphocysteamine, for more than six years. The patients were between two and three years of age at the start of the study. The daily dose of cysteamine was 60 mg/kg as cysteamine base. In all three, rapidly progressive renal failure occurred before their 10th birthday. When comparing their evolution with data on the natural history of childhood cystinosis, no improvement was observed in terms of growth and glomerular function. It is concluded that cysteamine therapy did not provide clear benefit to the three patients reported here.

UI MeSH Term Description Entries
D008297 Male Males
D001827 Body Height The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. Body Heights,Height, Body,Heights, Body
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D003543 Cysteamine A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS. Cysteinamine,Mercaptamine,2-Aminoethanethiol,Becaptan,Cystagon,Cysteamine Bitartrate,Cysteamine Dihydrochloride,Cysteamine Hydrobromide,Cysteamine Hydrochloride,Cysteamine Maleate (1:1),Cysteamine Tartrate,Cysteamine Tartrate (1:1),Cysteamine Tosylate,Cysteamine, 35S-Labeled,Mercamine,Mercaptoethylamine,beta-Mercaptoethylamine,2 Aminoethanethiol,35S-Labeled Cysteamine,Bitartrate, Cysteamine,Cysteamine, 35S Labeled,Dihydrochloride, Cysteamine,Hydrobromide, Cysteamine,Hydrochloride, Cysteamine,Tartrate, Cysteamine,Tosylate, Cysteamine,beta Mercaptoethylamine
D003554 Cystinosis A metabolic disease characterized by the defective transport of CYSTINE across the lysosomal membrane due to mutation of a membrane protein cystinosin. This results in cystine accumulation and crystallization in the cells causing widespread tissue damage. In the KIDNEY, nephropathic cystinosis is a common cause of RENAL FANCONI SYNDROME. Cystine Diathesis,Cystine Disease,Cystine Storage Disease,Cystinoses,Cystinosin, Defect of,Cystinosis, Nephropathic,Lysosomal Cystine Transport Protein, Defect Of,Nephropathic Cystinosis,Cystine Diatheses,Cystine Diseases,Cystine Storage Diseases,Cystinoses, Nephropathic,Defect of Cystinosin,Diatheses, Cystine,Diathesis, Cystine,Nephropathic Cystinoses,Storage Disease, Cystine,Storage Diseases, Cystine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

W Proesmans, and E Baten, and J Hoogmartens, and P Bruyneel
May 1981, The New England journal of medicine,
W Proesmans, and E Baten, and J Hoogmartens, and P Bruyneel
December 1985, The New England journal of medicine,
W Proesmans, and E Baten, and J Hoogmartens, and P Bruyneel
October 1995, Pediatric research,
W Proesmans, and E Baten, and J Hoogmartens, and P Bruyneel
January 1981, The New England journal of medicine,
W Proesmans, and E Baten, and J Hoogmartens, and P Bruyneel
May 2005, Medicine,
W Proesmans, and E Baten, and J Hoogmartens, and P Bruyneel
December 2003, European journal of pediatrics,
W Proesmans, and E Baten, and J Hoogmartens, and P Bruyneel
April 1987, The New England journal of medicine,
W Proesmans, and E Baten, and J Hoogmartens, and P Bruyneel
January 1983, Progress in clinical and biological research,
W Proesmans, and E Baten, and J Hoogmartens, and P Bruyneel
May 1983, American journal of ophthalmology,
W Proesmans, and E Baten, and J Hoogmartens, and P Bruyneel
June 2006, Ophthalmology,
Copied contents to your clipboard!